{
    "content": "Diagnosis:\tGlioblastoma multiforme (GBM), right temporal lobe, IDH-wildtype, MGMT promoter unmethylated, WHO Grade IV\n\t\tMetastatic breast cancer, previously treated, no evidence of active disease\n\nTimeline:\t2025-02-15: Diagnosis of GBM after seizure episode\n\t\tMRI brain: 4.5cm enhancing mass in the right temporal lobe with associated vasogenic edema and midline shift\n\t\t2025-03-01: Underwent subtotal resection of right temporal GBM\n\t\tPathology: WHO Grade IV glioblastoma, IDH-wildtype, MGMT unmethylated\n\t\t2025-03-25: Initiated concurrent temozolomide and radiotherapy (60Gy in 30 fractions)\n\t\tInitial response: Stable disease on post-treatment MRI, but residual edema present\n\nPrevious Cancer:\t2018-06-10: Diagnosed with Grade III invasive ductal carcinoma, left breast, ER+/PR+/HER2-\n\t\t2018-07-15: Left mastectomy and axillary dissection (2/15 nodes positive)\n\t\t2018-12-01: Completed adjuvant chemotherapy and chest wall radiotherapy\n\t\t2019-01-10: Commenced tamoxifen for 5 years, completed 2024\n\t\tCurrently: Under surveillance, no evidence of recurrence on mammogram (January 2025)\n\nCurrent Symptoms:\tFatigue, episodic headaches, left-sided weakness, and mild speech difficulty\n\nMedications:\tTemozolomide 150mg/m2 daily on 5/28 schedule\n\t\tDexamethasone 4mg twice daily (tapering)\n\t\tLevetiracetam 500mg twice daily\n\t\tPantoprazole 40mg daily\n\nFindings:\tMRI (2025-04-15): Persistent residual tumor with stable size but ongoing vasogenic edema\n\nPlan:\tContinue temozolomide maintenance for 6 cycles, reassess after cycle 3 with MRI\n\t\tStart physical therapy for left-sided weakness\n\t\tNeurology referral for seizure management optimization\n\t\tNext oncology follow-up in 4 weeks\n\t\tCoordinate palliative care input for symptom management",
    "output": {
        "primary_cancer": {
            "site": "brain, right temporal lobe",
            "year": 2025,
            "month": 2,
            "histopathology_status": "WHO Grade IV glioblastoma, IDH-wildtype, MGMT promoter unmethylated",
            "biomarker_status": "IDH-wildtype, MGMT unmethylated",
            "cancer_timeline": [
                {
                    "type": "anatomical_finding",
                    "value": "MRI brain shows 4.5cm enhancing mass in the right temporal lobe with associated vasogenic edema and midline shift",
                    "year": 2025,
                    "month": 2
                },
                {
                    "type": "treatment_surgery",
                    "value": "Subtotal resection of right temporal glioblastoma",
                    "year": 2025,
                    "month": 3
                },
                {
                    "type": "treatment_systemic_start",
                    "value": "Initiated concurrent temozolomide and radiotherapy (60Gy in 30 fractions)",
                    "year": 2025,
                    "month": 3
                },
                {
                    "type": "treatment_radiotherapy",
                    "value": "Initiated radiotherapy (60Gy in 30 fractions)",
                    "year": 2025,
                    "month": 3
                },                
                {
                    "type": "investigation_finding",
                    "value": "Post-treatment MRI shows stable disease with residual tumor and vasogenic edema",
                    "year": 2025,
                    "month": 4
                }
            ]
        },
        "other_cancers": [
            {
                "site": "breast, right",
                "year": 2018,
                "month": 6,
                "histopathology_status": "Grade III invasive ductal carcinoma",
                "biomarker_status": "ER+/PR+/HER2-",
                "latest_situation": "No evidence of active disease, under surveillance"
            }
        ],
        "patient_facts": [
            {
                "type": "current_symptom",
                "value": "Fatigue, episodic headaches, left-sided weakness, and mild speech difficulty"
            }
        ],
        "status_updates": [
            {
                "type": "clinical_summary",
                "value": "Glioblastoma multiforme with residual disease following subtotal resection and chemoradiotherapy. Continuing maintenence therapy, requires optimisation of seizure control."
            },
            {
                "type": "update_to_treatment",
                "value": "Continue temozolomide maintenance for 6 cycles, reassess after cycle 3 with MRI"
            },
            {
                "type": "follow_up_referral",
                "value": "Next oncology follow-up in 4 weeks"
            },
            {
                "type": "follow_up_referral",
                "value": "Neurology referral for seizure management optimization"
            },
            {
                "type": "follow_up_referral",
                "value": "Coordinate palliative care input for symptom management"
            },
            {
                "type": "planned_investigation",
                "value": "MRI reassessment after 3 cycles of temozolomide"
            }
        ]
    }
}